Immune System Diseases Completed Phase 1 Trials for Dapirolizumab pegol (DB16131)

Also known as: Immune System Disease

IndicationStatusPhase
DBCOND0029769 (Immune System Diseases)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01093911Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
NCT01764594Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus